IDEAYA Biosciences, Inc.
IDYA
Kedudukan dalam Saham
#4641
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Harga Saham
$33.89
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$3.27B
Perubahan (1 hari)
3.15%
Perubahan (1 tahun)
11.06%
Negara
US
Perdagangan IDEAYA Biosciences, Inc. (IDYA)
Kategori
Healthcare
Bilangan saham terbitan bagi IDEAYA Biosciences, Inc. (IDYA)
Bilangan saham terbitan setakat June 2026: 92.06M
Menurut laporan kewangan terkini dan harga saham IDEAYA Biosciences, Inc., bilangan saham terbitan semasa ialah 92.06M. Pada akhir December 2023, syarikat mempunyai 57.52M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk IDEAYA Biosciences, Inc. (IDYA) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 92.06M | 12.71% |
| 2024 | 81.68M | 42.00% |
| 2023 | 57.52M | 38.79% |
| 2022 | 41.44M | 17.57% |
| 2021 | 35.25M | 42.60% |
| 2020 | 24.72M | 22.18% |
| 2019 | 20.23M | 42.08% |
| 2018 | 14.24M | 0.00% |
| 2017 | 14.24M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 175.79% |
US
|
|
| 396.00M | 330.15% |
US
|
|
| 478.91M | 420.21% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -32.45% |
NL
|
